Table 1.

Characteristics of patients with malignant pleural mesothelioma

Patient	Age (years)	Sex	Stage	Treatment	Histology	Autoimmune
M1	56	Male	I	EPP	Sarcomatoid	–
M2	68	Male	III	EPP	Epithelioid	Membranous nephropathy
M3	57	Male	IV	SC	Epithelioid	ITP, hyperγglobulinemia
M4	64	Male	III	SC	Sarcomatoid	–
M5	76	Male	III	Chemotherapy	Sarcomatoid	–
M6	75	Male	II	EPP	Sarcomatoid	–
M7	61	Male	II	EPP	Epithelioid	–
M8	54	Male	III	EPP	Biphasic	–
M9	78	Male	I	Chemotherapy	Epithelioid	–
M10	65	Female	II	EPP	Epithelioid	–
M11	82	Male	III	SC	unknown	Unknown
M12	80	Male	III	SC	Epithelioid	Unknown
M13	55	Male	I	EPP	Epithelioid	–
M14	69	Male	II	SC	Epithelioid	–
M15	67	Male	III	EPP	Biphasic	–
M16	56	Male	IV	SC	Biphasic	–
M17	56	Male	IV	Chemotherapy	Sarcomatoid	–
M18	67	Male	III	EPP	Biphasic	–

M1 and M2 patients with malignant mesothelioma engrafted in SCID mice were studied.

M1–M18 patients had blood samples taken in order to analyze their antibody titers against the identified antigens.

EPP, extrapleural pneumonectomy; ITP, idiopathic thrombocytopenic purpura; SC, supportive care.